2022 Annual Meeting Videos
Day 1 – Friday
Day 2 – Saturday
2021 IBCN Update Series
IBCN Update on ctDNA Sept 25, 2021
IBCN Update on Bladder Preservation after Neoadjuvant Therapy Oct 30, 2021
IBCN Update on Biology of BCG Response Dec 4, 2021
2020 Annual Meeting Video Library
Annual Meeting Video
Oral Abstracts – Basic Science
Identification of New Driver and Passenger Mutations
Development and Characterization of a Novel Autochthonous Semi-spontaneous Bladder Cancer Model
STAG2 and PPARg as Drivers of Luminal-Type Bladder Cancer
Extraction-Free Comprehensive Transcriptome Squencing of Carcinoma In-SITU
Cisplatin-Based NAC
Oral Abstracts – Translational
Recurring Urothelial Carcinomas
Recombinant BCG Overexpressing STING Agonist
Molecular profiling of post-pembrolizumab muscle invasive bladder cancer (MIBC)
NER Pathway Deficiency in Bladder Cancer
Molecular Correlates of Cisplatin-based Chemotherapy
Oral Abstracts – Clinical
Results of a phase I/II single arm clinical trial assessing efficacy, safety and tolerability
Specific Genetic Susceptibility Patterns of the Urothelial Bladder Cancer Taxonomic Subtypes
Drug Repurposing for Bladder Cancer Driven by Patients’ Proteomic Signatures
Germline-somatic Interactions in the Bladder Cancer Genome
Impact of Upper Tract Urothelial Carcinoma on Outcomes of Non-Muscle Invasive Bladder Cancer
Posters – Translational
Investigating sexual dimorphism in the tumour immune microenvironment
Proteins Involved in Mitochondrial Biogenesis, Dynamics and Respiratory Complex I Activity
Organotypic model and in vitro modeling or urothelial carcinoma
An evaluation of single-sample tumor subtype classification methods
Cytotoxic and genotoxic effects of epigenetic inhibitors on bladder cancer cells
Tumor Immune Microenvironment in Responde to Radiotherapy vs BCG in a Murine Model of Bladder Cancer
An exploratory proteomic study delineating the local and systemic immune-oncologic profile of urinary bladder cancer patients
RBM10: The role of splicing factor in urothelial homeostatis and tumorigenesis
FBXW7 loss of function contributes to worse overall survival and associates with MYC accumulation
The potential for designing urothelial carcinomas using pluripotent stem cell-based systems
Genomic and transcriptomic characterization of metastatic urothelial carcinoma
Improving oncolytic virotherapy efficacy using target therapies against molecules of cell cycle control
Multiplex immunofluorescence to assess the tumor microenvironment in bladder cancer
Radiosensitization of bladder cancer cells via short-chain fatty acids and/or other metabolites produced by the gut microbiota
Regulation of PPARg expression in luminal muscle invasive bladder cancer
Heterogeneity-analysis of molecular subtypes of muscle-invasive bladder cancer
Mutational signature modelling
State-of-the-art Talks
The Ariadne’s Thread of FGFR3
Keynote: Improving Immune Checkpoint Inhibitor Therapy in Cancer
Posters – Clinical
Role of blue light cystoscopy in detecting invasive bladder tumor: Data from multi-institutional registry
Role of CA125 CA19-9 & CEA in predicting outcome
Age is associated with response to immune checkpoint blockade in advanced urothelial carcinoma
Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy
Divergent immunol correlates of PD-L1 scoring algorithms in muscle-invasive urothelial bladder cancer
Predictive and prognostic performance of IHC3-Uro immunohistochemistry-based molecular subtyping
Transition of ANXA10 expression is a useful dianostic and prognostic marker in upper tract urothelial carcinoma
Restaging Transurethral Resection of HG Ta Urothelial Carcinoma: A Risk-Adapted Approach
Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy
Measureable Absolute Basophil Count is Associated with Progression to Muscle Invasive Disease
CtDNA as a Predictor of Outcome
CBI after Turbt for Prevention of NMBIC Recurrence: A Systematic Review
Lytic Effects of Water on Bladder Cancer Cell Lines: Implications for CBI for Reduction of Recurrence
Protective effect of BCG bladder instillations on pneumonia?
Comparing Cost of Radical vs Partial Cystectomy for Patients Diagnosed with Localized Muscle-Invasive Bladder Cancer
Geographic Distribution of Racial Differences in Bladder Cancer Mortality in the United States
Long-Term Outcomes and Cost Among BCG-treated High Risk Non-Muscle Invasive Bladder Cancer Patients in an Equal Access Setting
Use of Psychotropic Drugs Among Bladder Cancer Patients in the United States
2020 UTMB Claywater Rounds
Inaugural Virtual Visiting Clawater Professor – Ashish Kamat, MD, MBBS
IBCN Update Series 2021
IBCN Update 2021 #2 Bladder Preservation after NAC
IBCN Update 2021 #3 Biology of BCG Response
IBCN Update 2021 #1 ctDNA